Australian Trial Cuts Melanoma Return Risk by Half

A groundbreaking Australian-led trial shows personalised mRNA therapy combined with immunotherapy cut melanoma recurrence by 49% in high-risk patients.

It's the first late-stage success for personalised cancer vaccines.